Jones Financial Companies Lllp Buys 12,457 Shares of Novartis AG $NVS

Jones Financial Companies Lllp raised its position in shares of Novartis AG (NYSE:NVS) by 7.2% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 185,573 shares of the company’s stock after purchasing an additional 12,457 shares during the period. Jones Financial Companies Lllp’s holdings in Novartis were worth $23,063,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in NVS. Brighton Jones LLC boosted its stake in Novartis by 76.5% in the fourth quarter. Brighton Jones LLC now owns 6,153 shares of the company’s stock worth $599,000 after buying an additional 2,666 shares in the last quarter. AQR Capital Management LLC lifted its holdings in shares of Novartis by 102.8% in the 1st quarter. AQR Capital Management LLC now owns 22,573 shares of the company’s stock worth $2,516,000 after acquiring an additional 11,444 shares during the last quarter. Empowered Funds LLC purchased a new stake in shares of Novartis in the 1st quarter valued at $1,764,000. Sivia Capital Partners LLC boosted its stake in shares of Novartis by 48.0% in the 2nd quarter. Sivia Capital Partners LLC now owns 7,959 shares of the company’s stock valued at $963,000 after purchasing an additional 2,581 shares in the last quarter. Finally, Simplicity Wealth LLC grew its holdings in shares of Novartis by 140.5% during the 2nd quarter. Simplicity Wealth LLC now owns 8,586 shares of the company’s stock valued at $1,039,000 after purchasing an additional 5,016 shares during the last quarter. Institutional investors own 13.12% of the company’s stock.

Novartis Trading Down 0.8%

Novartis stock opened at $149.83 on Wednesday. Novartis AG has a 12 month low of $97.71 and a 12 month high of $152.48. The company has a market capitalization of $316.51 billion, a price-to-earnings ratio of 20.47, a price-to-earnings-growth ratio of 1.97 and a beta of 0.50. The business’s fifty day simple moving average is $139.27 and its two-hundred day simple moving average is $130.20. The company has a current ratio of 0.88, a quick ratio of 0.68 and a debt-to-equity ratio of 0.50.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Novartis in a research report on Friday, January 16th. Weiss Ratings reissued a “buy (b)” rating on shares of Novartis in a research note on Monday, December 29th. Bank of America raised shares of Novartis from a “neutral” rating to a “buy” rating in a research note on Tuesday, November 25th. Wall Street Zen upgraded shares of Novartis from a “hold” rating to a “buy” rating in a report on Saturday, January 17th. Finally, Cfra set a $126.00 price target on shares of Novartis and gave the company a “hold” rating in a research report on Wednesday, October 29th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, seven have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $119.75.

Novartis Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.